---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022325"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:21:44.157885+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RenovoRx reports Q3 revenue $266K, net loss $2.9M; expands to 14 approved cancer centers

## Summary
- Q3 revenue $266K from RenovoCath sales; year-to-date revenue ~$900K from zero prior year.
- Net loss $2.9M for Q3 vs $2.5M in Q3 2024; cash $10M as of Sept 30, 2025.
- Phase III TIGeR-PaC trial enrollment expected to complete early 2026 with final data in 2027.
- Expanded from 5 to 14 approved cancer center customers for RenovoCath since start of 2025.
- Hired Philip Stocton as Senior Director of Sales and added two regional sales managers.

## SEC filing metadata
- accession: 0001493152-25-022325
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315225022325/0001493152-25-022325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315225022325/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022325
- JSON: https://secwatch.observer/filing/0001493152-25-022325.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022325.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.